Trump pharma deals may undercut Medicare drug price reforms

Private agreements between Trump administration and drugmakers reportedly trade Medicaid price concessions for protection from Medicare cuts, potentially weakening drug pricing reforms. Analysts suggest these deals could offset intended savings and shift costs to Medicare. The full scope and legal basis remain unclear.